Polymer Nanocarriers for MicroRNA Delivery

Overview

Journal J Appl Polym Sci

Publisher Wiley

Date 2021 Jan 1

PMID 33384460

Citations 20

Authors

Chintan H Kapadia

Benjamin Luo

Megan N Dang

NDea Irvin-Choy

Danielle M Valcourt

Emily S Day

Affiliations

Soon will be listed here.

Abstract

Abnormal expression of microRNAs (miRNAs), which are highlyconserved noncoding RNAs that regulate the expression of various genes post transcriptionally to control cellular functions, has been associated with the development of many diseases. In some cases, disease-promoting miRNAs are upregulated, while in other instances disease-suppressive miRNAs are downregulated. To alleviate this imbalanced miRNA expression, either antagomiRs or miRNA mimics can be delivered to cells to inhibit or promote miRNA expression, respectively. Unfortunately, the clinical translation of bare antagomiRs and miRNA mimics has been challenging because nucleic acids are susceptible to nuclease degradation, display unfavorable pharmacokinetics, and cannot passively enter cells. This review emphasizes the challenges associated with miRNA mimic delivery and then discusses the design and implementation of polymer nanocarriers to overcome these challenges. Preclinical efforts are summarized, and a forward-looking perspective on the future clinical translation of polymer nanomaterials as miRNA delivery vehicles is provided.

Citing Articles

Advances in nucleic acid delivery strategies for diabetic wound therapy.

Sarthi S, Bhardwaj H, Jangde R J Clin Transl Endocrinol. 2024; 37:100366.

PMID: 39286540 PMC: 11404062. DOI: 10.1016/j.jcte.2024.100366.

Crosstalk between MiRNAs/lncRNAs and PI3K/AKT signaling pathway in diabetes mellitus: Mechanistic and therapeutic perspectives.

Aghaei-Zarch S Noncoding RNA Res. 2024; 9(2):486-507.

PMID: 38511053 PMC: 10950585. DOI: 10.1016/j.ncrna.2024.01.005.

Exploring the Therapeutic Significance of microRNAs and lncRNAs in Kidney Diseases.

Bravo-Vazquez L, Paul S, Colin-Jurado M, Marquez-Gallardo L, Castanon-Cortes L, Banerjee A Genes (Basel). 2024; 15(1).

PMID: 38275604 PMC: 10815231. DOI: 10.3390/genes15010123.

miR-142: A Master Regulator in Hematological Malignancies and Therapeutic Opportunities.

Huang W, Paul D, Calin G, Bayraktar R Cells. 2024; 13(1).

PMID: 38201290 PMC: 10778542. DOI: 10.3390/cells13010084.

Regulation and therapeutic potentials of microRNAs to non-small cell lung cancer.

Le M, Nguyen H, Nguyen X, Do X, Mai B, Ngoc Nguyen H Heliyon. 2023; 9(11):e22080.

PMID: 38058618 PMC: 10696070. DOI: 10.1016/j.heliyon.2023.e22080.

References

Yin H, Kanasty R, Eltoukhy A, Vegas A, Dorkin J, Anderson D . Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014; 15(8):541-55. DOI: 10.1038/nrg3763. View

Macfarlane L, Murphy P . MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2011; 11(7):537-61. PMC: 3048316. DOI: 10.2174/138920210793175895. View

Madaan K, Kumar S, Poonia N, Lather V, Pandita D . Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci. 2014; 6(3):139-50. PMC: 4097927. DOI: 10.4103/0975-7406.130965. View

Goedeke L, Salerno A, Ramirez C, Guo L, Allen R, Yin X . Long-term therapeutic silencing of miR-33 increases circulating triglyceride levels and hepatic lipid accumulation in mice. EMBO Mol Med. 2014; 6(9):1133-41. PMC: 4197861. DOI: 10.15252/emmm.201404046. View

Layzer J, McCaffrey A, Tanner A, Huang Z, Kay M, Sullenger B . In vivo activity of nuclease-resistant siRNAs. RNA. 2004; 10(5):766-71. PMC: 1370566. DOI: 10.1261/rna.5239604. View

Lu J, Wang X, Marin-Muller C, Wang H, Lin P, Yao Q . Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009; 9(4):325-41. PMC: 2701163. DOI: 10.1586/erm.09.15. View

Yang Q, Lai S . Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015; 7(5):655-77. PMC: 4515207. DOI: 10.1002/wnan.1339. View

Liechty W, Kryscio D, Slaughter B, Peppas N . Polymers for drug delivery systems. Annu Rev Chem Biomol Eng. 2012; 1:149-73. PMC: 3438887. DOI: 10.1146/annurev-chembioeng-073009-100847. View

Taratula O, Garbuzenko O, Savla R, Wang Y, He H, Minko T . Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes. Curr Drug Deliv. 2010; 8(1):59-69. DOI: 10.2174/156720111793663642. View

10.

Zhou J, Wu J, Hafdi N, Behr J, Erbacher P, Peng L . PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun (Camb). 2006; (22):2362-4. DOI: 10.1039/b601381c. View

11.

Cho Y, Kim J, Park K . Polycation gene delivery systems: escape from endosomes to cytosol. J Pharm Pharmacol. 2003; 55(6):721-34. DOI: 10.1211/002235703765951311. View

12.

Nishio H, Masumoto H, Sakamoto K, Yamazaki K, Ikeda T, Minatoya K . MicroRNA-145-loaded poly(lactic-co-glycolic acid) nanoparticles attenuate venous intimal hyperplasia in a rabbit model. J Thorac Cardiovasc Surg. 2018; 157(6):2242-2251. DOI: 10.1016/j.jtcvs.2018.08.115. View

13.

Qian X, Ren Y, Shi Z, Long L, Pu P, Sheng J . Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy. Mol Pharm. 2012; 9(9):2636-45. DOI: 10.1021/mp3002039. View

14.

Panyam J, Labhasetwar V . Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003; 55(3):329-47. DOI: 10.1016/s0169-409x(02)00228-4. View

15.

Goyal R, Kapadia C, Melamed J, Riley R, Day E . Layer-by-layer assembled gold nanoshells for the intracellular delivery of miR-34a. Cell Mol Bioeng. 2018; 11(5):383-396. PMC: 6289203. DOI: 10.1007/s12195-018-0535-x. View

16.

Guo L, Lu Z . The fate of miRNA* strand through evolutionary analysis: implication for degradation as merely carrier strand or potential regulatory molecule?. PLoS One. 2010; 5(6):e11387. PMC: 2894941. DOI: 10.1371/journal.pone.0011387. View

17.

Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M . MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008; 456(7224):980-4. DOI: 10.1038/nature07511. View

18.

Murchison E, Hannon G . miRNAs on the move: miRNA biogenesis and the RNAi machinery. Curr Opin Cell Biol. 2004; 16(3):223-9. DOI: 10.1016/j.ceb.2004.04.003. View

19.

Waite C, Sparks S, Uhrich K, Roth C . Acetylation of PAMAM dendrimers for cellular delivery of siRNA. BMC Biotechnol. 2009; 9:38. PMC: 2679008. DOI: 10.1186/1472-6750-9-38. View

20.

Gironella M, Seux M, Xie M, Cano C, Tomasini R, Gommeaux J . Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A. 2007; 104(41):16170-5. PMC: 2042180. DOI: 10.1073/pnas.0703942104. View